{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060230","form_type":"8-K","ticker":"MNKD","cik":"0000899460","company_name":"MANNKIND CORP","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.339682+00:00","generated_at":"2026-06-08T18:36:45.698423+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MannKind Q3 total revenue $51M, up 56% YoY; net income $2M GAAP","bullets":["Total revenue $51.3M, +56% YoY; net income $2M (GAAP); non-GAAP net income $4M.","Tyvaso DPI royalties $20.2M, +225% YoY, driven by patient demand.","Afrezza net revenue $13.5M, +24% YoY on higher demand and price; V-Go down 18%.","Cash and investments $144.3M; R&D spending rose to $10M (vs $4.1M) on pipeline MNKD-101.","Commercial product gross margin improved to 78% from 69% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060230","json":"https://secwatch.observer/filing/0000950170-23-060230.json","markdown":"https://secwatch.observer/filing/0000950170-23-060230.md","text":"https://secwatch.observer/filing/0000950170-23-060230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899460/000095017023060230/0000950170-23-060230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899460/000095017023060230/mnkd-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T18:36:45.698423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04ee65663fff83b714ba9d493d3d603f9b7687a4","claim":"MANNKIND CORP reported quarter ended September 30, 2023 results: revenue Total revenues of $51M, net income Net income of $2M.","evidence_excerpt":"--- EX-99.1 EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2023 THIRD QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) • 3Q 2023 Total revenues of $51M; +56% vs. 3Q 2022 • 3Q YTD 2023 Total revenues of $140M; +121% vs. 3Q YTD 2022 • 3Q 2023 Net income of $2M; Non-GAAP net income of $4M • 3Q 2023 Tyvaso DPI royalties of $20M;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899460/000095017023060230/0000950170-23-060230-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Revenue","value":"Total revenues of $51M"},{"label":"Net income","value":"Net income of $2M"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}